Palisade Bio director repeat buying

Conviction: 62% · Horizon: 6M · 2026-07-09
Board member scales an existing micro-cap stake at a higher price within one week

A director purchased twice in about a week, increasing commitment from roughly $59k to over $102k and paying up from about $1.98 to about $2.04, with total holdings exceeding 416,000 shares. That pattern fits informed conviction rather than a token starter position in a clinical-stage biotech.

Instrument Side Target Reason
PALI Long Paying a higher price on a second open-market buy soon after the first, with a six-figure stake and a large existing holding, is among the strongest discretionary insider signals available in sub-$2 biotech names.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.